$0.33
-0.03 (-9.30%)
Open$0.36
Previous Close$0.36
Day High$0.36
Day Low$0.32
52W High$1.58
52W Low$0.26
Volume—
Avg Volume1.12M
Market Cap53.16M
P/E Ratio—
EPS$-0.19
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+6,899.1% upside
Current
$0.33
$0.33
Target
$22.81
$22.81
$15.42
$22.81 avg
$25.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 168.58M | 149.35M | 36.22M |
| Net Income | -21,971,030 | -17,517,653 | -2,507,722 |
| Profit Margin | -13.0% | -12.4% | -6.9% |
| EBITDA | -12,591,160 | -10,596,741 | -3,086,652 |
| Free Cash Flow | — | — | -2,753,402 |
| Rev Growth | +12.9% | +12.9% | +20.2% |
| Debt/Equity | 9.81 | 9.81 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |